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Abstract
We investigated bacteraemia trends for ﬁve major bacterial pathogens, Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae,
Enterococcus faecalis and Enterococcus faecium, and determined how expanding antimicrobial resistance inﬂuenced the total burden of bac-
teraemias in Europe. Aetiological fractions of species and antibiotic phenotypes were extracted from the European Antimicrobial Resis-
tance Surveillance System (EARSS) database for laboratories, which consistently reported between 2002 and 2008. Trend analyses used
generalized linear models. Robustness of results was assessed by iterative analysis for different geographic regions. From 2002 to 2008,
the overall number of reports increased annually by 6.4% (95% conﬁdence interval (CI) 6.2–6.5%), from 46 095 to 67 876. In the subset
of laboratories providing denominator information, the overall incidence increased from 0.58/1000 patient-days to 0.90/1000 patient-
days (7.2% per year; 95% CI 6.9–7.5%). The frequency of reported bacteraemia isolates of S. aureus and Streptococcus pneumoniae
increased moderately, while increase in E. coli and Enterococcus faecium was more pronounced. Bacteraemias caused by methicillin-resis-
tant S. aureus increased until 2005 (7.6% per year; 95% CI 6.1–9.1%), and then decreased ()4.8% per year; 95% CI )6.1 to )3.5%),
whereas the number attributable to methicillin-sensitive S. aureus increased continuously (3.4% per year; 95% CI 3.0–3.7). Increasing
rates of E. coli were mainly caused by antibiotic-resistant phenotypes. Our data suggest that the burden of bacterial bloodstream infec-
tion has been increasing for all species during EARSS surveillance. Trends were mainly driven by resistant strains and clearly dissociated
between resistant and susceptible isolates. It appears that infections with resistant clones add to rather than replace infections caused
by susceptible bacteria. As a consequence, expansion of antibiotic resistance creates an additional strain on healthcare systems.
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Introduction
It has been suggested that, more than 23 000 people died of
Staphylococcus aureus and Escherichia coli bacteraemias in Eur-
ope in 2007 alone [1]. At the same time, bacteraemias seem
to be rising in numbers [2–4], although most of the recent
investigations have focused on S. aureus at national level. It
remains unclear whether these trends can be generalized
across species and across Europe. It is also unknown what
may cause this dynamic; (i) changes in pathogen-speciﬁc
transmissibility, virulence or resistance, (ii) new ecological
opportunities linked to an aging population or increasingly
complex medical care, or (iii) a combination of these. Alter-
natively, we could be merely seeing some random ﬂuctuation
at regional levels or an increase in detection rates caused by
better diagnostic practices.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
One of the possible, adaptive responses of bacteria under
antibiotic selection includes the emergence of antimicrobial
resistance. A number of observational studies have suggested
that resistant strains cause additional infections rather than
replacing those caused by susceptible bacteria [5–8]. This
hypothesis was ﬁrst put forward by Boyce et al. [9]. and was
based on data for S. aureus from single centres or countries.
The European Antimicrobial Resistance Surveillance Sys-
tem (EARSS, renamed EARS-Net in 2010), maintains the larg-
est database of routinely collected antibiotic susceptibility
data for bacteraemia isolates worldwide [10]. Since its launch
in 1999, the initiative has grown in scope and size. Over the
last 10 years, antibiotic susceptibility test (AST) results for
seven major pathogens from more than 900 000 bacteraemic
episodes have been reported by over 900 laboratories from
33 countries in Europe [11]. The EARSS participants have
been using consistent protocols and frequently provide
denominator data so this dataset provides a useful tool to
describe the changing epidemiology of bacteraemias for dif-
ferent species and different species-speciﬁc resistance traits.
On the basis of surveillance data, we here describe the tem-
poral dynamics of ﬁve major pathogens (S. aureus, E. coli,
Streptococcus pneumoniae, Enterococcus faecalis and Enterococ-
cus faecium) causing bacteraemias between 2002 and 2008,
and explore how antimicrobial resistance impinges on the
total burden of bacteraemias in Europe.
Material and Methods
Data consisted of routine AST results reported to EARSS
for primary isolates (ﬁrst isolate per species per patient per
year) of ﬁve bacterial species causing bloodstream infections;
S. aureus, Streptococcus pneumoniae (since 1999), E. coli,
Enterococcus faecalis and Enterococcus faecium (since 2001).
Participating laboratories routinely include all diagnostic
blood cultures that become positive for the above-men-
tioned species and report results through their laboratory
information system using a standardized digital communica-
tion tool. Data for the ﬁrst year of reporting were excluded
to correct for potential inconsistencies introduced at the
start of the surveillance initiative. Data collected after the
transfer of the network to the European Centre for Disease
Prevention and Control in 2009 were excluded to rule out
possible artefacts caused by changes in hospital and labora-
tory coding. Analyses are therefore based on data reported
to EARSS between 2002 and 2008. The AST results were
ascertained according to agreed protocols [12] and the gen-
eral quality and comparability of these data were evaluated
by annual external quality assessment exercises [11]. For
detailed trend analyses, reports for S. aureus and E. coli were
stratiﬁed by class-speciﬁc susceptibility patterns: S. aureus,
b-lactams (J01C and D); E. coli, aminopenicillins (J01CA:
ampicillin or amoxicillin), aminoglycosides (J01GB: gentamicin,
tobramycin or amikacin), ﬂuoroquinolones (J01MA: ciproﬂox-
acin, oﬂoxacin or levoﬂoxacin) and third generation cephalo-
sporins (J01DD: ceftriaxone, ceftazidime or cefotaxime).
Class resistance was deﬁned as resistance to at least one
antimicrobial compound within each ATC category. Informa-
tion concerning denominator data including type of hospital,
number of patient-days, number of hospital beds, occupancy
and total number of blood culture isolates, was available for
5 years (2002, 2004, 2006, 2007 and 2008) [11,13].
Selected datasets
We included data from laboratories that consistently
reported AST results between 2002 and 2008 (Subset A).
Consistency was regarded as quarterly reporting of bacterae-
mias by the laboratory identiﬁable by laboratory identiﬁca-
tion code in the surveillance database. Subset A consisted of
438 laboratories (71% of laboratories participating in 2002)
from 27 countries (96% of countries participating in 2002)
reporting 410 333 bacteraemias (66% of the total number of
cases). Incidence densities were calculated for institutions,
which reported both AST and denominator data between
2002 and 2008 (Subset AD). Subset AD consisted of 136
(22%) laboratories from 12 (43%) countries, reporting
149 933 (24%) bacteraemias. For a more inclusive analysis of
all countries participating in EARSS in 2008, all data reported
for 2008 were used for subset 2008A. Incidence densities
for 2008 were obtained for laboratories that reported both
AST and denominator data (Subset 2008AD, 62% of 2008
laboratories, 61% of 2008 bacteraemias) (Table 1).
Statistical analysis
Incidence densities were based on the number of reported
bacteraemia isolates per 1000 patient-days. The number of
patient-days was approximated by multiplying the number of
reported beds per hospital with 365.25 days assuming an
80% bed occupancy (mean European bed occupancy) [11].
The average annual increase in bacteraemias was calculated
using generalized linear models with Poisson distribution and
loglink function with year as the independent variable. Spe-
cies-speciﬁc trends were compared with the overall trend by
including the overall number of bacteraemia isolates as a
baseline (offset). Trends in resistance phenotypes were mod-
elled by including each phenotype as a dependent variable in
a separate generalized linear model. The signiﬁcance of
trends was determined at the conventional probability
threshold of p <0.05 using the Wald test.
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Countries were grouped by resistance levels for methicil-
lin-resistant S. aureus (MRSA) and third-generation cephalo-
sporin-resistant E. coli (G3CREC) as well as geography.
Region I (low resistance, North) included Denmark, Finland,
Iceland, the Netherlands, Norway and Sweden; Region II
(intermediate resistance, West) included Austria, Belgium,
France, Germany, Ireland, Luxemburg and the UK); Region
III (intermediate resistance MRSA, high resistance for
G3CREC, East) included Bulgaria, Croatia, Czech Republic,
Estonia, Hungary, Latvia, Lithuania, Poland, Romania and
Slovenia; Region IV (high resistance, South) included Cyprus,
Greece, Israel, Italy, Malta, Portugal, Spain and Turkey.
Data were analysed using SAS 9.2. For all estimates 95%
conﬁdence intervals (95% CI) were reported.
Results
Changes over time
The total number of episodes reported between 2002 and
2008 for all ﬁve pathogens increased by 47% from 46 095 to
67 876 between 2002 and 2008 (Subset A). This corre-
sponds to an annual increase of 6.4% (95% CI 6.2–6.5%).
Although consistent for all ﬁve pathogens, the fastest
increase (in rate) was observed for Enterococcus faecium
(1118 in 2002 to 3128 in 2008; annual increase 19.3%; 95%
CI 18.3–20.3%) and the largest increase (in volume) was
observed for E. coli (20 151 in 2002 to 32 194 in 2008;
annual increase 8.1%; 95% CI 7.8–8.3%) (Fig. 1, Table 2).
Analyses of incidence densities (Subset AD), based on a sub-
sample of laboratories that provided denominator informa-
tion, conﬁrmed these trends. (see Supplementary
information, Table S1).
For S. aureus, the frequency of MRSA increased, from
3297/15 422 (21%) in 2002 to 4230/18 003 (23%) in 2005
(Subset A). Then the trend reversed and frequencies
decreased to 3628/18 894 (19%) in 2008. Between 2002 and
2005 the annual increase was 7.6% (95% CI 6.1–9.1%), fol-
lowed by an average annual decrease of )4.8% (95% CI )6.1
to )3.5%). Independent of the biphasic behaviour of MRSA,
reports of methicillin-susceptible S. aureus (MSSA) consis-
tently increased from 12 125 to 15 266 (period 1: 4.0%; 95%
CI 3.2–4.8%; period 2: 3.6%; 95% CI 2.8–4.3%; Wald test for
differences in trends: p 0.27).
TABLE 1. Number of laboratories
(number of isolates reported) that
consistently reported Staphylococ-
cus aureus, Escherichia coli, Strepto-
coccus pneumoniae, Enterococcus
faecium or Enterococcus faecalis
bacteremias to the European Anti-
microbial Resistance Surveillance
System database in the different
subsets, displayed per country
Country
Subset A Subset AD Subset 2008A Subset 2008AD
2002–2008 2002–2008 + DI 2008 2008 + DI
Austria 10 (12 910) – 38 (6110) 37 (5822)
Belgium 81 (28 204) – 103 (4219) 26 (1219)
Bosnia and Herzegovina – – 3 (140) –
Bulgaria 13 (2021) 10 (1642) 23 (406) 20 (381)
Croatia 13 (8652) 11 (7829) 19 (1721) 18 (1711)
Cyprus – – 5 (309) 5 (309)
Czech Republic 41 (29 967) 41 (28 464) 47 (5579) 47 (5479)
Denmark 5 (15 449) – 15 (6517) –
Estonia 8 (2794) 6 (1769) 11 (603) 11 (598)
Finland 12 (20 647) – 15 (4056) 4 (595)
France 19 (34 024) 11 (23 270) 158 (14 485) 153 (13 956)
Germany 4 (4 118) – 14 (3354) –
Greece 28 (13 787) – 46 (3322) –
Hungary 19 (11 476) – 26 (2832) 16 (1728)
Iceland 2 (1732) 2 (1647) 2 (249) 2 (220)
Ireland 21 (21 409) – 41 (4243) 33 (4092)
Israel 5 (12 867) 4 (8607) 5 (1641) 3 (1118)
Italy 26 (16 355) – 32 (2687) 18 (1694)
Latvia – – 12 (322) 12 (322)
Lithuania – – 13 (696) 12 (652)
Luxembourg 4 (2198) – 6 (537) 4 (307)
Malta 1 (1734) 1 (1637) 1 (285) 1 (285)
the Netherlands 8 (13 430) – 18 (4701) 4 (664)
Norway 11 (18 803) – 13 (3612) 8 (2427)
Poland 13 (1455) – 39 (293) –
Portugal 15 (14 874) 12 (13 398) 22 (4029) 20 (3861)
Romania 3 (491) – 6 (125) –
Slovenia 10 (8907) 10 (8727) 10 (1697) 10 (1667)
Spain 25 (30 482) 9 (11 408) 32 (6827) 26 (5459)
Sweden 21 (51 312) 19 (41 535) 21 (8713) 21 (7887)
Switzerland – – 22 (4856) –
Turkey – – 16 (3566) 16 (3566)
UK 20 (30 235) – 55 (7294) 21 (927)
Total 438 (410 333) 136 (149 933) 889 (110 026) 548 (66 946)
Subset A: laboratories that consistently reported antibiotic susceptibility test (AST) results between 2002 and 2008.
Subset AD: laboratories that consistently reported AST and denominator results between 2002 and 2008.
Subset 2008A: laboratories that reported AST results for 2008.
Subset 2008AD: laboratories that reported AST and denominator results for 2008.
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For E. coli, complete AST results (aminopenicillins, ﬂuor-
oquinolones, aminoglycosides and third-generation cephalo-
sporins) were available for 84% of all reports (Subset A).
The frequency of reported E. coli infections increased
irrespective of resistance (Fig. 2). However, the number of
reported bacteraemias caused by G3CREC showed the
steepest rise, with an average annual increase of 29.9% (95%
CI 28.2–31.5%, Fig. 3). The latter group also contained the
largest number of combined resistance; 76% were reported
co-resistant to ﬂuoroquinolones, and 48% to aminoglyco-
sides, (Table 3). The number of resistant phenotypes
expanded faster than infections caused by susceptible
isolates, leading to a decrease in the proportion susceptible
from 51% in 2002 to 42% in 2008 (Fig. 3).
In 2008, 110 026 bacteraemia isolates were reported,
(Subset 2008A), of which a majority (61%, 66 946) could be
used to derive incidence densities based on available denomi-
nator data (Subset 2008AD, Table 1). Escherichia coli was the
most frequent causative pathogen, representing 47% of the
reports and occurring at a density of 0.29/1000 patient-days,
followed by S. aureus (29% of all reports, 0.19/1000 patient-
days), Streptococcus pneumoniae (11%, 0.05/1000 patient-
days), Enterococcus faecalis (9%, 0.06/1000 patient-days) and
Enterococcus faecium (5%, 0.03/1000 patient-days). The most
frequent resistance phenotype, among all evaluated patho-
gen–compound combinations, was ﬂuoroquinolone-resistance
in E. coli (9% of all reported isolates, 0.08/1000 patient-days),
followed by methicillin-resistance among S. aureus (6%, 0.05/
1000 patient-days) and third-generation cephalosporin-resis-
tance in E. coli isolates (3%, 0.03/1000 patient-days).
Region-speciﬁc changes
In all four deﬁned geographic regions (see Material and
methods), the reports for E. coli, Streptococcus pneumoniae,
Enterococcus faecalis and Enterococcus faecium bacteraemias
increased between 2002 and 2008 (Subset A). Reports for
S. aureus in Region II (West) remained relatively stable (see
Supporting information, Table S2), which was a result of the
decrease in MRSA bacteraemias in this region between 2005
Pathogen 2002 2003 2004 2005 2006 2007 2008 
E. coli 
S. aureus 
S. pneumoniae 
E. faecalis 
E. faecium 
20 151 22 620 24 371 27 328 29 543 30 931 32 194 
15 422 17 325 17 550 18 003 18 210 18 665 18 894 
5725 6674 6721 7458 7051 7421 7555
3679 4309 4625 5201 5837 6012 6105
1118 1374 1563 2091 2541 2938 3128
FIG. 1. Trends in the total number of
Staphylococcus aureus, Escherichia coli,
Streptococcus pneumoniae, Enterococcus
faecium and Enterococcus faecalis bactera-
emia isolates reported to the European
Antimicrobial Resistance Surveillance
System between 2002 and 2008. Only
laboratories that consistently reported
for all years were included.
TABLE 2. Average annual change in the frequency of Staph-
ylococcus aureus, Escherichia coli, Streptococcus pneumoniae,
Enterococcus faecium and Enterococcus faecalis bacteraemias
reported to the European Antimicrobial Resistance Surveil-
lance System between 2002 and 2008, expressed as abso-
lute change and relative change above or below the average
for all species combined.
Species
Change per
year in %
(95% CI) p-value
Relative change
per year in %
(95% CI) p-value
E. coli 8.1 (7.8–8.3) <0.01 1.7 (1.4–1.9) <0.01
S. aureus 2.8 (2.5–3.1) <0.01 )3.4 ()3.7 to ).1) <0.01
Streptococcus
pneumoniae
3.8 (3.4–4.3) <0.01 )2.4 ()2.9 to ).0) <0.01
Enterococcus
faecalis
8.7 (8.2–9.3) <0.01 2.3 (1.7–2.8) <0.01
Enterococcus
faecium
19.3 (18.3–20.3) <0.01 12.4 (11.5–13.4) <0.01
All species
combined
6.4 (6.2–6.5) <0.01 –
Only laboratories that consistently reported for all years were included. Results
are based on generalized linear models s with Poisson distribution.
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and 2008. This region-speciﬁc trend was mainly responsible
for the overall decrease of MRSA within the EARSS during
this period. Over the same time the number of MRSA
increased in Region III (East). Irrespective of MRSA trends,
all regions reported rising levels of MSSA (see Supporting
information, Table S3). Rapid expansion of G3CREC bacte-
raemias was observed in all regions as well, although the rise
was less pronounced for countries in region IV (South) (see
Supporting information, Table S4).
The distribution of pathogens in 2008 was similar for all
regions, with E. coli being the most prevalent bacterium among
the ﬁve included pathogens (see Supporting information,
Table S5) and ﬂuoroquinolone-resistant E. coli (range 0.04–
0.15/1000 patient-days) being the most common identiﬁed
resistance phenotype (see Supporting information, Table S6).
Discussion
Data regarding the dynamics of invasive infections are crucial
to inform the public health debate about prioritization in
healthcare. We demonstrated that the number of bactera-
emia isolates reported to the EARSS for ﬁve major bacterial
species, S. aureus, E. coli, Streptococcus pneumoniae, Enterococ-
cus faecium and Enterococcus faecalis, causing bacteraemia
have markedly increased in 27 European countries between
2002 and 2008. Within these 7 years, absolute numbers
increased by 47% at an annual average of 6.4%. Notably,
E. coli (20 151 reported in 2002 and 32 194 reported in
2008, 8.7% annual increase) and Enterococcus faecium bacte-
raemias (1118 reported in 2002 and 3128 reported in 2008,
19.3% annual increase) showed the most signiﬁcant changes.
For E. coli this trend was mainly the result of an expansion in
antibiotic-resistant strains, often featuring multi-drug resis-
tance. For Enterococcus faecium the frequency of multi-resis-
tant isolates also increased. Low numbers, however,
precluded statistical conﬁrmation of this trend (data not
shown). Reports for S. aureus increased at more moderate
rates (2.8% per year). This could be attributed to a decline
in MRSA after 2005, whereas MSSA showed a steady upward
trend in almost all regions.
The strength of the present study lies in its inclusiveness
and representativeness. The analyses incorporated data
about ﬁve major pathogens from more than 1000 hospitals
serving large geographic areas, and comprising 7 years of
continuous reporting. A limitation of the present study is the
lack of consistent data about blood culture frequency at lab-
oratory level. Rising investigation density could artiﬁcially
increase case ascertainment. Denominator data from EARSS,
however, indicate that the overall number of blood culture
Resistance pattern 
Aminoglycoside 
resistance (%) 
0.5 Susceptible to all three antibiotic classes 
Resistant to: 
3.1 aminopenicillins 
8.4 fluoroquinolones 
26.8 aminopenicillins + fluoroquinolones 
aminopenicillins + third-generation cephalosporins 22.8  
55.6 All three antibiotic classes 
FIG. 2. Total number of Escherichia coli
bacteraemia isolates with different resis-
tance phenotypes reported to the
European Antimicrobial Resistance Sur-
veillance System between 2002 and
2008. Only laboratories that consistently
reported for all years were included.
R = resistance; G3C = third-generation
cephalosporins; FQ = ﬂuoroquinolones;
amipn = aminopenicillins. For reasons of
clarity, combined resistance proportions
for aminoglycosides are exclusively dis-
played in a Table.
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sets per 1000 patient-days did not markedly change over the
years [11,13]. Increasing hospital activity, could also explain
the increasing number of reported bacteraemia isolates.
Therefore, trend analyses were repeated with incidence den-
sities of bacteraemias in the subset of laboratories providing
denominator data. This takes into account changes in the
number of admissions as well as changes in length of stay.
These analyses conﬁrmed that the upward trends were real
for this subset of participating laboratories. As the number
of reports increased in all four geographical regions simulta-
neously, change in investigation density (ascertainment bias)
was an unlikely explanation for the observed trends.
Several studies describing trends of bacteraemias have
been published. A recent paper of Laupland et al [14].
reported decreasing rates for S. aureus in four different
regions within Denmark. This may be associated with low
levels of MRSA in the selected areas (overall MRSA incidence
1.9/100 000 patient-days versus 4.4/100 000 patient-days in
the present study). We also reported relatively small
TABLE 3. Percent of combined resistance for Escherichia coli
bacteraemia isolates (n = 156 751) reported to the Euro-
pean Antimicrobial Resistance Surveillance System between
2002 and 2008.
Susceptible
AMIPN FQ AMINO G3C
34 2 0.2 0
AMIPN
S 4 0.9 0
R 29 12 9
FQ
S 43 2 1
R 88 30 20
AMINO
S 47 12 2
R 94 76 32
G3C
S 48 14 5
R 100 76 48
Overall 50 16 7 4
Resistance proportions (%) to one class of antibiotics was calculated in the
absence (S) and presence (R) of resistance to each of the other classes: amin-
openicillins (AMIPN), ﬂuoroquinolones (FQ), aminoglycosides (AMINO) and
third-generation cephalosporins (G3C). Only laboratories that consistently
reported for all years were included.
1
2
3
4
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6
7
2002 2003 2004 2005 2006 2007 2008
Year
R
el
at
iv
e 
in
cr
ea
se
 (2
00
2 
= 
in
de
x)
Susceptible G3CR FQR AminoR AmipnR
Resistance pattern Number Change per year 
80022002 in % (CI95)
Susceptible 8068 12 092 6.2 (5.8–6.6) 
G3CR 321 1785 29.9 (28.2–31.5) 
FQR 1796 5613 19.3 (18.6–20.1) 
aminoR 823 2138 17.2 (16.0–18.4) 
amipnR 7613 14 400 11.1 (10.7–11.5) 
Total isolates tested 15 952 27 214 8.8 (8.6–9.1) 
FIG. 3. Relative increase in the number
of Escherichia coli bacteraemia isolates
with different resistance phenotypes
(index year = 2002) reported to the
European Antimicrobial Resistance Sur-
veillance System between 2002 and
2008. Only laboratories that consistently
reported for all years were included.
Symbols indicate ascertained values and
lines are based on generalized linear
models with Poisson distribution. Num-
bers and the average annual increase
per phenotype are displayed in the
table. R = resistance; G3C = third-gen-
eration cephalosporins; FQ = ﬂuoro-
quinolones; amino = aminoglycosides;
amipn = aminopenicillins.
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increases for S. aureus, especially in areas with decreasing
levels of MRSA. A report from England, Wales and Northern
Ireland [3], and two single centre studies from Spain [15]
and Israel [16] reported a similar secular increase in the fre-
quency of bacteraemias. In all countries this observation
could be mainly attributed to a rising number of infections
with gram-negative bacteria [3,15,16].
Accepting that the observed trends are real, what could
be the cause? The included surveillance data did not provide
enough detail to be able to investigate the inﬂuence of
healthcare-associated or community-associated infections, or
the impact of changes in case mix over time. However, hos-
pitals are facing a relative increase of elderly patients
[2,5,15–17]. At the same time, there is a growing proportion
of patients who receive complex medical care and are subse-
quently exposed to more invasive devices [15,18]. These
changes may have increased the ecological opportunities for
opportunistic bacteria to cause invasive infections [19], and
could account for the overall increase of bacteraemias. In
addition, emergence and global expansion of highly success-
ful, resistant clones, such as Enterococcus faecium CC17 and
E. coli ST131, could be associated with higher prevalence of
infections caused by resistant strains [19–22]. For S. aureus,
major pandemic MRSA clones are found as well. However,
the spread of MRSA is oligo-clonal with different regions
affected by genetically unrelated lineages of potentially differ-
ential ﬁtness [23,24]. This could explain why western coun-
tries reported decreasing trends, while eastern European
countries still face an increasing prevalence of MRSA. How-
ever, trends may have also been reversed as a result of the
successful implementation of extensive infection control pro-
grammes, like those speciﬁcally aimed at reducing the inci-
dence of MRSA in UK [25,26] and French [27] hospitals.
It therefore seems that trends are increasing most rapidly
for species for which international, antibiotic-resistant clones
have been described. At the same time, invasive infections
caused by susceptible bacteria also show a monotonous
increase albeit at a lower rate. This suggests that emergence
of antimicrobial resistance does not replace infections caused
by susceptible strains, but rather causes additional infections
[9,28]. Although recent data showed that addition or
replacement of susceptible infections by resistant ones may
differ between regions [14] and this requires further study.
In conclusion, this study conﬁrmed that the burden of bac-
teraemias is increasing in European hospitals. The increase is
ubiquitous and can be observed for gram-negative as well as
for gram-positive pathogens. The main driving forces behind
this rise remains to be elucidated, but the expansion of
successful antibiotic resistant clones among an increasingly
vulnerable hospital population remains the most compelling
explanation for the observed trends. Notably, expansion of
antimicrobial resistance seems to create an additional strain
on healthcare systems by further increasing the burden of
disease caused by difﬁcult-to-treat bacteraemias in Europe.
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Table S1. Average annual change in the incidence den-
sity per 1000 patient-days of Staphylococcus aureus, Escherichia
coli, Streptococcus pneumoniae, Enterococcus faecium or Entero-
coccus faecalis bacteraemias as reported to the European
Antimicrobial Resistance Surveillance System between 2002
and 2008. Only laboratories that consistently reported and
provided denominator data for all years were included.
Results are based on generalized linear models with Poisson
distribution.
Table S2. Average annual change in the number of
Staphylococcus aureus, Escherichia coli, Streptococcus pneumo-
niae, Enterococcus faecium and Enterococcus faecalis bactera-
emia isolates reported to the European Antimicrobial
Resistance Surveillance System between 2002 and 2008,
overall and per region, expressed as absolute change and rel-
ative change above or below the average for all species com-
bined. Only laboratories that consistently reported for all
years were included. Results are based on generalized linear
models with Poisson distribution.
Table S3. Average annual change in the number of
methicillin-resistant (MRSA) and methicillin-susceptible
(MSSA) Staphylococcus aureus bacteraemia isolates reported
to the European Antimicrobial Resistance Surveillance Sys-
tem between 2002 and 2008, overall and per region. Only
laboratories that consistently reported for all years were
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included. Separate estimates are given for the period before
and after the tipping point of the MRSA trend in 2005.
Results are based on generalized linear models with Poisson
distribution.
Table S4. Average annual change in the number of
Escherichia coli bacteraemia isolates resistant to third-genera-
tion cephalosporins (G3C), ﬂuoroquinolones (FQ), aminogly-
cosides (AMINO) or aminopenicillins (AMIPN) reported to
the European Antimicrobial Resistance Surveillance System
between 2002 and 2008, overall and per region. Only labora-
tories that consistently reported for all years were included.
Results are based on generalized linear models with Poisson
distribution.
Table S5. Frequency (fraction of total number of bac-
teraemia isolates reported per region) of Escherichia coli,
Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus
faecalis and Enterococcus faecium bacteraemia isolates
reported to the European Antimicrobial Resistance Surveil-
lance System in 2008, displayed per region.
Table S6. Number of bacteraemia isolates (percentage
resistant) and incidence density per 1000 patient-days of ﬂu-
oroquinolone-resistant Escherichia coli (FLUO), methicillin-
resistant Staphylococcus aureus (MRSA) and third-generation
cephalosporin-resistant E. coli (G3CREC) bacteraemias
reported to the European Antimicrobial Resistance Surveil-
lance System in 2008, displayed per region.
Please note: Wiley Blackwell is not responsible for the con-
tent or functionality of any supporting materials supplied by
the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
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